NYSE:BSXMedical Equipment
Does Boston Scientific’s 2026 Double-Digit Sales Outlook and Leadership Shift Change The Bull Case For BSX?
Boston Scientific’s fourth-quarter 2025 results, reported on February 4, 2026, showed sales rising to US$5,286 million and net income to US$672 million, alongside full-year sales of US$20.07 billion and net income of US$2.90 billion, while director Yoshiaki Fujimori later confirmed he will not stand for re-election at the 2026 Annual Meeting.
The company coupled this earnings report with guidance calling for double-digit reported and organic net sales growth in 2026, even as investors...